The World Health Organization (WHO) has recently listed Gram-negative ?superbugs? Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii as the most critical pathogens, which are the greatest threat to human health. Due to the slow progress in development of novel antibiotics, polymyxins are often used as the last-line therapy against Gram-negative infections; however, clinical studies have shown that the efficacy of parenteral polymyxins is disappointing for the treatment of Gram-negative lung infections due to very low exposure of the drug to the infection site at the airway surface and dose-limiting kidney toxicity. More worrying is the development of polymyxin resistance induced by the polymyxin monotherapy. One of the promising strategies for the treatment of Gram-negative lung infections is direct delivery of synergistic polymyxin combinations to the infection sites at the airway surface. However, conventional nebulization has low delivery efficiency; even worse, current colistin methanesulfonate (CMS) nebulization therapies are empirical and have never been systematically optimized using pharmacokinetic/pharmacodynamic/toxicodynamic (PK/PD/TD). The overall aim of this project is to develop novel liposomal therapies for combinational antibiotics using innovative spray-freeze-drying powder production technology, cutting-edge imaging, systems pharmacology and mechanism-based pharmacokinetic/pharmacodynamic/toxicodynamic (PK/PD/TD) modeling.
The Specific Aims are: (1) to develop novel liposomal formulations of polymyxin combinations using innovative spray-freeze- drying technology; (2) to determine in vitro pharmacodynamics of the formulations; (3) to elucidate the disposition of polymyxin combinations from the formulations in the airway using cutting-edge imaging and the mechanisms of potential pulmonary toxicities using systems pharmacology; (4) to apply mechanism-based PK/PD/TD modeling to optimizing dosage regimens of the superior liposomal formulation in rodent lung infection models. To combat the emergent global antimicrobial crisis, we must outpace the evolution of ?superbugs? by novel strategies. With the disappointing progress in developing new antibiotic against MDR Gram-negative pathogens, our innovative multi-disciplinary project addresses NIAID?s strategic approach ?extending the clinical utility of antibacterial drugs?optimizing use of existing drugs and combination therapies to suppress emergence of resistance and minimize toxicity?. The success of our work will have a broader impact to the USA and global health as the platform can be readily applied to develop superior new therapies for other respiratory infections such as pulmonary tuberculosis.
Antimicrobial resistance is one of the greatest threats to the global health. Polymyxins have been increasingly used as the last-resort therapy against multidrug resistant Gram-negative `superbugs'; however, the efficacy of parental polymyxins in the treatment of lung infections is very disappointing. We aims to employ innovative multidisciplinary approaches to develop novel liposomal therapies of synergistic polymyxin combinations to provide much safer and more efficacious therapies against deadly Gram-negative lung infections.
